Leo Pavliv Net Worth

The estimated Net Worth of Leo Pavliv is at least $980 Thousand dollars as of 18 March 2013. Mr. Pavliv owns over 160,000 units of Cumberland Pharmaceuticals stock worth over $304,306 and over the last 15 years he sold CPIX stock worth over $0. In addition, he makes $675,844 as Executive Vice President - Operations and Chief Development Officer at Cumberland Pharmaceuticals.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Pavliv CPIX stock SEC Form 4 insiders trading

Leo has made over 5 trades of the Cumberland Pharmaceuticals stock since 2009, according to the Form 4 filled with the SEC. Most recently he exercised 160,000 units of CPIX stock worth $560,000 on 18 March 2013.

The largest trade he's ever made was exercising 160,000 units of Cumberland Pharmaceuticals stock on 18 March 2013 worth over $560,000. On average, Leo trades about 7,346 units every 45 days since 2009. As of 18 March 2013 he still owns at least 225,395 units of Cumberland Pharmaceuticals stock.

You can see the complete history of Mr. Pavliv stock trades at the bottom of the page.

Leo Pavliv biography

Leo B. Pavliv serves as Executive Vice President - Operations, Chief Development Officer of the Company., is Executive Vice President - Operations, Chief Development Officer of the Company. Mr. Pavliv has served as our Vice President, Operations since 2003 was named Senior Vice President in 2009 and Chief Development Officer in 2012. He is responsible for Cumberland’s overall drug development, including manufacturing and quality operations, and has over 29 years of experience developing pharmaceutical and biological products. From 1997 to 2003, he worked at Cato Research, a contract research organization, most recently as Vice President of Pharmaceutical Development where he oversaw development of a wide variety of products throughout the development cycle. Prior to 1997, he held various scientific and management positions at both large pharmaceutical and smaller biopharmaceutical firms including Parke-Davis from 1984 to 1986, Agouron Pharmaceuticals from 1992 to 1997, ProCyte from 1989 to 1992, and Interferon Sciences from 1986 to 1989. He is a registered pharmacist (R.Ph.) and is regulatory affairs certified. Mr. Pavliv holds a B.S., Pharmacy, and an M.B.A. from Rutgers University.

What is the salary of Leo Pavliv?

As the Executive Vice President - Operations and Chief Development Officer of Cumberland Pharmaceuticals, the total compensation of Leo Pavliv at Cumberland Pharmaceuticals is $675,844. There are 2 executives at Cumberland Pharmaceuticals getting paid more, with A. Kazimi having the highest compensation of $1,477,300.

How old is Leo Pavliv?

Leo Pavliv is 59, he's been the Executive Vice President - Operations and Chief Development Officer of Cumberland Pharmaceuticals since 2017. There are 16 older and 3 younger executives at Cumberland Pharmaceuticals. The oldest executive at Cumberland Pharmaceuticals Inc. is Jonathan Griggs, 85, who is the Independent Director.

What's Leo Pavliv's mailing address?

Leo's mailing address filed with the SEC is 2525 WEST END AVE., SUITE 950, NASHVILLE, TN, 37203.

Insiders trading at Cumberland Pharmaceuticals

Over the last 15 years, insiders at Cumberland Pharmaceuticals have traded over $4,393,644 worth of Cumberland Pharmaceuticals stock and bought 265,077 units worth $1,208,228 . The most active insiders traders include Joey A Jacobs, Leo Pavliv, and Thomas R Lawrence. On average, Cumberland Pharmaceuticals executives and independent directors trade stock every 29 days with the average trade being worth of $10,407. The most recent stock trade was executed by Caroline Young on 1 December 2022, trading 379 units of CPIX stock currently worth $849.

What does Cumberland Pharmaceuticals do?

cumberland pharmaceuticals is a specialty pharmaceutical company whose mission is to acquire currently marketed and late-stage development pharmaceutical products and grow them through marketing to targeted, underserved physician segments. cumberland is dedicated to providing high quality products which address unmet medical needs.

Complete history of Mr. Pavliv stock trades at Cumberland Pharmaceuticals

Cumberland Pharmaceuticals executives and stock owners

Cumberland Pharmaceuticals executives and other stock owners filed with the SEC include:

• A. Kazimi,
  Chairman of the Board, Chief Executive Officer
• A. J. Kazimi,
  Founder, Chairman, Pres & CEO
• Leo Pavliv,
  Executive Vice President - Operations, Chief Development Officer
• Leo B. Pavliv,
  Exec. VP of Operations & Chief Devel. Officer
• Martin Cearnal,
  Executive Vice President, Chief Commercial Officer, Director
• Martin E. Cearnal,
  Exec. VP, Chief Commercial Officer & Director
• James Herman,
  Vice President - National Accounts, Chief Compliance Officer
• James Lowrance Herman,
  Sr. VP of National Accounts & Chief Compliance Officer
• Michael Bonner,
  Senior Director Finance and Accounting and Chief Financial Officer
• Caroline Young,
  Independent Director
• Kenneth Krogulski,
  Independent Director
• James Jones,
  Independent Director
• Joey Jacobs,
  Independent Director
• Jonathan Griggs,
  Independent Director
• Joseph Galante,
  Independent Director
• Gordon Bernard,
  Independent Director
• Erin Smith Gull,
  Sr. Corp. Relations Associate
• Adam S. Mostafa,
  Managing Director
• Cindy B. Patton,
  Sr. Director of Field Marketing
• Jean W. Marstiller,
  Sr. VP of Admin. Services & Corp. Sec.
• John Michael Hamm,
  Director of Fin. & Accounting and CFO
• Thomas R Lawrence,
  Director
• Martin S Jr Brown,
  
• Chris T. Bitterman,
  Vice Pres Sales & Marketing
• Rick Scott Greene,
  Chief Financial Officer
• Robert Edwards,
  Director
• Jean W Marstiller,
  Sr. VP & Corp. Secretary
• Lawrence W Greer,
  Director
• David L Lowrance,
  Vice President and CFO
• Todd M. Anthony,
  Vice Pres Organizational Dev
• John M. Hamm,
  VP Chief Financial Officer